Stock AEON AEON BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages AEON Biopharma, Inc.

Equities

AEON

US00791X1000

Market Closed - Nyse
Other stock markets
 04:00:00 2024-06-10 pm EDT 		5-day change 1st Jan Change
1.5 USD -10.71% Intraday chart for AEON Biopharma, Inc. -8.54% -79.17%
May. 16 AEON Biopharma, Inc. Announces Termination of Peter Reynolds as Chief Financial Officer, Effective May 17, 2024 CI
May. 16 AEON Biopharma, Inc. Announces Executive Changes CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
AEON Biopharma, Inc. Announces Executive Changes
AEON Biopharma, Inc. Deloitte, Inc. Announces Update of Phase 2 Double Blind Study of ABP-450 in the Treatment of Migraine
AEON Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
AEON Biopharma, Inc. Provides Update on Development Pipeline
US Equity Markets Close Higher Friday Following Weak Jobs Report
Sector Update: Health Care Stocks Mixed Late Afternoon
Sector Update: Health Care
Top Midday Decliners
Sector Update: Health Care Stocks Mixed Pre-Bell Friday
AEON Biopharma Shares Slump Pre-Bell After Failed Chronic Migraine Phase 2 Trial
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
Sector Update: Health Care Stocks Slide Late Afternoon
Sector Update: Health Care
AEON Biopharma Shares Tumble on Wider Q4 Loss
AEON Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
AEON Biopharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
AEON Biopharma, Inc. Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
Sector Update: Health Care Stocks Mixed Premarket Friday
AEON Biopharma Says Cervical Dystonia Treatment Well-Tolerated in Phase 2 Study
AEON Biopharma, Inc. Presents Positive Clinical and Pre-Clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, At TOXINS 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AEON Stock
  4. News AEON Biopharma, Inc.
  5. Other languages